Clinical features, treatment and outcome in neurosarcoidosis: systematic review and meta-analysis
Drs. D. Fritz, Prof. Dr. D. van de Beek, Dr. M.C. Brouwer
In this article we collected information of all the large studies which describe patients diagnosed with neurosarcoidosis to give an adequate overview of clinical characteristics (symptoms), ancillary investigations, treatment and outcome in neurosarcoidosis. The conclusion is that the disease is diverse (a cameleon) and that despite the introduction of new third line treatment agents still one-third of patients remain stable, deteriorate or die.
Off-labelgebruik van biologicals voor zeldzame immunologische aandoeningen
Anne Musters, Amira Assaf, Dominique L.P. Baeten en Sander W. Tas
Patients with serious, immune-mediated inflammatory diseases (IMID's), like sarcoidosis, are increasingly treated with biologicals. Because research in these rare diseases is often very difficult, it is not known in all cases what the effects of the treatment are. In this article we elaborate on the RUBRIC-registry, in which we registrate the efficacy and the safety of these agents.